Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Avenanthramide B is a naturally occurring phenolic alkaloid found primarily in oats (*Avena sativa*). It is a conjugate of ferulic acid and 5-hydroxyanthranilic acid. Biologically, it acts as a potent anti-inflammatory agent by inhibiting the **NF-κB** (nuclear factor kappa B) pathway, thereby reducing the expression of pro-inflammatory cytokines. It also exhibits antioxidant, anti-itch, and anti-melanogenic properties, the latter through the inhibition of tyrosinase and melanogenesis. While it is a key active component in FDA-approved colloidal oatmeal skin protectants used for conditions like atopic dermatitis and eczema, avenanthramide B itself is primarily utilized as a research tool and analytical standard in studies concerning cardiovascular health (atherosclerosis), oncology, and dermatology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on avenanthramide B.